Modulation of Gamma-Secretase for the Treatment of Alzheimer's Disease

@inproceedings{Tate2012ModulationOG,
  title={Modulation of Gamma-Secretase for the Treatment of Alzheimer's Disease},
  author={Barbara Tate and Timothy D. Mckee and Robyn M. B. Loureiro and Jo Ann Dumin and Weiming Xia and Kevin Pojasek and Wesley F. Austin and Nathan O. Fuller and Jed L. Hubbs and Ruichao Shen and Jeff Jonker and Jeff Ives and Brian Scott Bronk},
  booktitle={International journal of Alzheimer's disease},
  year={2012}
}
The Amyloid Hypothesis states that the cascade of events associated with Alzheimer's disease (AD)-formation of amyloid plaques, neurofibrillary tangles, synaptic loss, neurodegeneration, and cognitive decline-are triggered by Aβ peptide dysregulation (Kakuda et al., 2006, Sato et al., 2003, Qi-Takahara et al., 2005). Since γ-secretase is critical for Aβ production, many in the biopharmaceutical community focused on γ-secretase as a target for therapeutic approaches for Alzheimer's disease… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

Natural Product and Natural Product-Derived Gamma Secretase Modulators from Actaea Racemosa Extracts

Mark A. Findeis, Frank C. Schroeder, Steffen P. Creaser, Timothy D. McKee, Weiming Xia
  • Medicines
  • 2015
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers

  • The Journal of pharmacology and experimental therapeutics
  • 2016
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea racemosa.

Mark A. Findeis, Frank C. Schroeder, +8 authors Christopher B. Eckman
  • ACS chemical neuroscience
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Aminocyclohexanes and aminotetrahydropyrans as γ-secretase modulators and their preparation and use for thetreatment of neurological and psychiatric diseases

E.C.W. Am
  • pp. 91, Pfizer, USA, 2011.
  • 2011
VIEW 1 EXCERPT